Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

NCT05292443 is registered in ClinicalTrials.gov with Geneplus-Beijing Co. Ltd. as lead sponsor.

NCT NCT05292443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05292443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
Lead sponsor
Geneplus-Beijing Co. Ltd.
Phase
Observational
Overall status
Withdrawn
Start date
December 20, 2021
Completion date
March 17, 2023
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

combined hepatocellular-cholangiocarcinoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, primary liver cancer